Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC
Erica C. Nakajima, Nicole Drezner, Xiaoxue Li, et al.
Clinical Cancer Research (2021) Vol. 28, Iss. 8, pp. 1482-1486
Open Access | Times Cited: 216

Showing 1-25 of 216 citing articles:

Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
John H. Strickler, Hironaga Satake, Thomas J. George, et al.
New England Journal of Medicine (2022) Vol. 388, Iss. 1, pp. 33-43
Open Access | Times Cited: 256
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Md Entaz Bahar, Hyun Joon Kim, Deok Ryong Kim
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 224
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Marwan Fakih, Lisa Salvatore, Taito Esaki, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 23, pp. 2125-2139
Closed Access | Times Cited: 157
Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance
Jia‐Jia Wu, Zhenghong Lin
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 15056-15056
Open Access | Times Cited: 95
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
Jessica Lee, Smruthy Sivakumar, Alexa B. Schrock, et al.
npj Precision Oncology (2022) Vol. 6, Iss. 1
Open Access | Times Cited: 73
Translating p53-based therapies for cancer into the clinic
Sylvain Peuget, Xiaolei Zhou, Galina Selivanova
Nature reviews. Cancer (2024) Vol. 24, Iss. 3, pp. 192-215
Closed Access | Times Cited: 55
Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Sahar F. Bannoura, Husain Yar Khan, Asfar S. Azmi
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 61
KRAS in NSCLC: State of the Art and Future Perspectives
Priscilla Cascetta, Arianna Marinello, Chiara Lazzari, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5430-5430
Open Access | Times Cited: 43
Nanomedicine Combats Drug Resistance in Lung Cancer
Xiuli Zheng, Xiao-Hai Song, Guonian Zhu, et al.
Advanced Materials (2023) Vol. 36, Iss. 3
Closed Access | Times Cited: 35
Erianin inhibits the growth and metastasis through autophagy-dependent ferroptosis in KRASG13D colorectal cancer
Qun Miao, Wei-Qing Deng, Wen-Yu Lyu, et al.
Free Radical Biology and Medicine (2023) Vol. 204, pp. 301-312
Closed Access | Times Cited: 32
Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer—Advances and Challenges
Attila A. Seyhan
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13340-13340
Open Access | Times Cited: 29
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Guowei Yin, Jing Huang, Johnny Petela, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27
Epigenetic regulation in lung cancer
Shahin Ramazi, Maedeh Dadzadi, Zahra Sahafnejad, et al.
MedComm (2023) Vol. 4, Iss. 6
Open Access | Times Cited: 26
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
Bruna Pellini, Russell W. Madison, Merrida Childress, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 22, pp. 4596-4605
Open Access | Times Cited: 22
The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer
Vishnu Kumarasamy, Jianxin Wang, Costakis Frangou, et al.
Cancer Research (2024) Vol. 84, Iss. 7, pp. 1115-1132
Open Access | Times Cited: 14
HSP70-mediated mitochondrial dynamics and autophagy represent a novel vulnerability in pancreatic cancer
Giulia D. S. Ferretti, Colleen E. Quaas, Irene Bertolini, et al.
Cell Death and Differentiation (2024) Vol. 31, Iss. 7, pp. 881-896
Open Access | Times Cited: 14
Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors
Marcell Baranyi, Eszter Molnár, Luca Hegedűs, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 6, pp. 1059-1072
Open Access | Times Cited: 12
Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges
Attila A. Seyhan
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7974-7974
Open Access | Times Cited: 11
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, et al.
Current Oncology (2024) Vol. 31, Iss. 4, pp. 2024-2046
Open Access | Times Cited: 10
The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma
Faria Nusrat, Akshay Khanna, Aditi Jain, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 2103-2103
Open Access | Times Cited: 9
Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
Lee Jy, Richie R. Bhandare, Sai H. S. Boddu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116275-116275
Open Access | Times Cited: 8
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer
Ferdinandos Skoulidis, Bob T. Li, Maximilian J. Hochmair, et al.
The Oncologist (2025) Vol. 30, Iss. 1
Open Access | Times Cited: 1
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance
Martin Sattler, Atish Mohanty, Prakash Kulkarni, et al.
Trends in cancer (2022) Vol. 9, Iss. 1, pp. 42-54
Open Access | Times Cited: 28
The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
Simon Manuel Tria, Matthew Burge, Vicki Whitehall
Cancers (2023) Vol. 15, Iss. 8, pp. 2375-2375
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top